Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015119 | 1.00 | ATM (0.43) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL18015134 | 1.00 | ATM (0.43) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL18015115 | 0.88 | ALOX5AP (0.45) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL18015118 | 0.88 | ALOX5AP (0.45) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL18015133 | 0.88 | ALOX5AP (0.45) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL18015128 | 0.84 | PDE8B (0.43) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL19779316 | 0.84 | PDE8B (0.43) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL18015127 | 0.84 | PDE8B (0.43) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL26796816 | 0.83 | HSD17B10 (0.46) | ATMHSD17B10ALDH1A1ALOX5APFEN1 | |
| SCHEMBL18849728 | 0.82 | ATM (0.50) | ATMHSD17B10ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016227-A1 | PROCESS FOR THE SYNTHESIS OF DIFLUOROMETHYL ETHER-BASED COMPOUNDS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-01-18 | — | — | US | disclosed |
| WO-2016123707-A1 | PROCESS FOR THE SYNTHESIS OF DIFLUOROMETHYL ETHER-BASED COMPOUNDS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016227-A1 | PROCESS FOR THE SYNTHESIS OF DIFLUOROMETHYL ETHER-BASED COMPOUNDS | CYP2F1, CYP2E1, PAH | ATM 2969/4885HSD17B10 193/4885ALDH1A1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.